Definium Therapeutics (DFTX) Non-Current Assets (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Non-Current Assets data on file, last reported at $20.7 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 61.34% year-over-year to $20.7 million in Q1 2026; TTM through Mar 2026 was $138.5 million, a 20.45% increase from a year earlier, with the FY2025 full-year figure at $20.8 million, up 1.21% from the prior year.
• Non-Current Assets for Q1 2026 stood at $20.7 million, roughly flat from $20.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for DFTX reached as high as $76.0 million in Q2 2025 and fell as low as $20.1 million in Q1 2024.
• Historically, Non-Current Assets has averaged $27.1 million across 5 years, with a median of $21.5 million in 2023.
• Across the five-year window, Non-Current Assets soared 271.38% in 2025 and slumped 61.34% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $23.9 million in 2022, then fell by 13.66% to $20.7 million in 2023, then retreated by 0.67% to $20.5 million in 2024, then advanced by 1.21% to $20.8 million in 2025, then decreased by 0.24% to $20.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $20.7 million in Q1 2026, $20.8 million in Q4 2025, and $21.1 million in Q3 2025.